BioSpace News Archive

Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter ended March 31, 2022 and reaffirmed its financial guidance for the year.

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, reported financial results for the three months ended March 31, 2022.

Treace Medical Concepts, Inc. today reported financial results for the first quarter ended March 31, 2022.

Celldex Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2022.

Ardelyx, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2022.

BioMarin Pharmaceutical Inc. announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise.

Natera, Inc., a global leader in cell-free DNA testing, reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business progress and financial outlook.

Tivity Health, Inc. (Nasdaq: TVTY) (the “Company”), a leading provider of healthy life-changing solutions, including SilverSneakers®, today announced financial results for the first quarter ended March 31, 2022.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022, after the U.S. financial markets close.